BioStock: Elicera on CAR T-cells’ potential beyond blood cancer

CAR T-cell therapy is an emerging form of immunotherapy that has shown promising potential in, among other areas, various forms of blood cancer. However, this form of treatment has recently indicated additional areas of use such as in solid tumours and autoimmune diseases. BioStock contacted Elicera Therapeutics, Sweden's only R&D company developing and evaluating CAR T-cells, to comment on the progress in the field.

Read the interview with Elicera Therapeutics CEO Jamal el-Mosleh at biostock.se:

https://www.biostock.se/en/2023/03/elicera-on-car-t-cells-potential-beyond-blood-cancer

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/